Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date: July 28, 2016

The Manager
Dept. of Corporate Services – Listing
The Bombay Stock Exchange Limited
P J Tower, Dalal Street
Mumbai – 400 001

The Manager- Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra – East,
Mumbai - 400051

Dear Sir,

Sub: Press Release

Please find enclosed a copy of press release made by the Company, on the topic:

'Biocon Initiates "EK Prayaas" Nationwide Awareness Program on Hepatitis C'

Request you to kindly take the above intimation on record.

Thanking you,

Yours faithfully,

For Biocon Limited,

BIOCON LIMITED ☆ BANGALORE ☆

Authorised Signatory

Press Note

Biocon Initiates "EK Prayaas" Nationwide Awareness Program on Hepatitis C

Bengaluru, India: July 28th, 2016:

Biocon Branded Formulations business announced the launch of a new patient support program "Ek Prayaas" through a nationwide awareness drive for Hepatitis C on the occasion of 'World Hepatitis Day' -28th July, 2016.

Biocon's Virology Division set up in April 2015, is driven with a mission of "Saving Lives" with a prime focus on HCV. The 'Ek Prayaas' program in collaboration with healthcare professionals will organize a nationwide HCV awareness campaign across tier I and tier II cities. The program is aimed to educate the common man about the causes and effects of Hepatitis C. According to WHO July, 2016 data, 130-150 million people globally have chronic Hepatitis C infection. It is estimated that over 18^ million in India are affected by Hepatitis C.

The Biocon Virology division though in its infancy is extensively engaged with Gastroenterologists, Hepatologists, Blood Banks and Deaddiction Centres to create awareness about HCV, updating HCPs on the recommended HCV management approaches and paving the way towards HCV eradication.

Commenting on this program, Prakash S Kayal, Senior Director and Business Head, Virology Division, Biocon said: *"Hepatitis C (HCV) is a neglected disease, with very little public awareness on disease and its implications, if left untreated. With the advent of advanced therapies, Hep C is curable if diagnosed and treated on time. Through 'Ek Prayaas' we aim to increase public awareness on Hep C , enabling early diagnosis and treatment to combat HCV and save several innocent lives. Together with our partners we hope to eradicate HCV in India."*

Biocon has introduced several lifesaving therapies in this segment with a clear focus on being highly scientific, patient centric and access oriented.

Hepatitis-C is a viral disease that causes liver inflammation leading to diminished liver function or liver failure. It is referred to as a "silent epidemic" as most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which may take decades.

Chronic HCV infection could lead to scarring and poor liver function (cirrhosis) over many years, resulting in complications such as bleeding, jaundice, fluid accumulation in the abdomen, infections and liver cancer. Hepatitis C is a silent killer disease, it does not cause any obvious symptoms, and people may have it and not even know, HCV virus proliferates in

liver cells and over a period of time cause fibrosis, cirrhosis, hepatocellular carcinoma, which is a leading cause of liver transplant or death.

Building awareness about this asymptomatic disease leading to timely diagnosis is imperative for HCV eradication.

^Source: WHO, 1997 report.

About Biocon Ltd:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of biologics, novels as well as biosimilars, differentiated small molecules and affordable rh- insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb ™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin. Visit: www.biocon.com

For More Information Contact:	
Media Relations	
Seema Ahuja	**Chidananda BA**
VP & Global Head of Communications	Deputy Manager-Corporate Communications
Biocon Limited	Biocon Limited
T: +91-80-2808-2222, M:+919972317792	T: +91 80 28082221, M:+918970935708
Email: seema.ahuja@biocon.com	Email: chidananda.ba@biocon.com